Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Liabilities (2022 - 2025)

Taysha Gene Therapies' Total Liabilities history spans 4 years, with the latest figure at $97.6 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 6.72% year-over-year to $97.6 million; the TTM value through Sep 2025 reached $97.6 million, up 6.72%, while the annual FY2024 figure was $88.8 million, 9.16% down from the prior year.
  • Total Liabilities for Q3 2025 was $97.6 million at Taysha Gene Therapies, up from $84.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $244.9 million in Q3 2023 and bottomed at $83.3 million in Q1 2025.
  • The 4-year median for Total Liabilities is $99.1 million (2024), against an average of $111.0 million.
  • The largest annual shift saw Total Liabilities soared 144.05% in 2023 before it tumbled 62.67% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $125.3 million in 2022, then dropped by 21.97% to $97.8 million in 2023, then dropped by 9.16% to $88.8 million in 2024, then increased by 9.82% to $97.6 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Total Liabilities are $97.6 million (Q3 2025), $84.6 million (Q2 2025), and $83.3 million (Q1 2025).